Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma
BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1
will include patients with asymptomatic brain metastases and cohort 2 will include patients
with symptomatic brain metastasis.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español Multidisciplinar de Melanoma
Collaborators:
MFAR MFAR Clinical Research S.L. Pierre Fabre Medicament